Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 9/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 2/20 | 0.30 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.30 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20154481 | 0.88 | PIK3CD (0.40) | PIK3CDRETCCR2GRM5RIPK1 | |
| SCHEMBL21158721 | 0.82 | PIK3CD (0.36) | PIK3CDRETGRM5RIPK1HRH3 | |
| SCHEMBL20070420 | 0.79 | PIK3CD (0.49) | PIK3CDRETCCR2HRH3 | |
| SCHEMBL23126226 | 0.78 | RET (0.37) | PIK3CDRETGRM5RIPK1NAMPT | |
| SCHEMBL23555271 | 0.78 | RET (0.35) | PIK3CDRETGRM5RIPK1NAMPT | |
| SCHEMBL20070417 | 0.76 | SMN1; SMN2 (0.35) | PIK3CDRETGRM5RIPK1 | |
| SCHEMBL20154483 | 0.74 | PIK3CD (0.45) | PIK3CDRETCCR2HRH3 | |
| SCHEMBL20160371 | 0.73 | RET (0.36) | RETCCR2 | |
| SCHEMBL22031247 | 0.72 | PIK3CD (0.44) | PIK3CDRETCCR2GRM5RIPK1 | |
| SCHEMBL20071302 | 0.72 | HRH3 (0.40) | PIK3CDCCR2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134702-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134702-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | PIK3CD 1191/4885RET 1/4885CCR2 1878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.